FOLH1 and prostate carcinoma: PSMA overexpression in men with prostate carcinoma has been leveraged in the development of theragnostic PSMA targeting radionuclides, including FDA approved Lu177 Vipivotide Tetraxetan, providing sensitive and specific serial PET monitoring while also improving the management of PSMA positive, hormone refractory PCA [15–18].